X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: UPPTHERA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 28, 2021
Details:
HitGen has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. Identified compounds will be exclusively licensed to UPPTHERA for further development.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Sky9 Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 18, 2021
Details:
The funds will be mainly used to enhance its artificial intelligence (AI)-driven novel drug R&D platform, accelerate the preclinical development of several new medicine pipelines and expand international business cooperation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Xencor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 07, 2020
Details:
Under the terms of the agreement, Xencor, Inc., gets rights to Biocytogen’s fully human antibody RenMab™/RenLite™ Mouse platform to enhance Xencor’s monoclonal antibody drug discovery research.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Exscientia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 09, 2020
Details:
Under this collaboration, Exscientia will use its advanced Centaur Chemist AI platform to design new molecules against project specific targets and Huadong will apply its experimental and managerial capabilities to support Exscientia’s AI design in a rapid closed-loop cycle.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
